Cipher Pharmaceuticals (CPHR.F) Stock Overview
Operates as a specialty pharmaceutical company in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CPHR.F from our risk checks.
CPHR.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Cipher Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$13.50 |
| 52 Week High | CA$14.00 |
| 52 Week Low | CA$7.47 |
| Beta | 0.52 |
| 1 Month Change | 25.71% |
| 3 Month Change | 23.88% |
| 1 Year Change | 70.28% |
| 3 Year Change | 433.72% |
| 5 Year Change | 1,147.74% |
| Change since IPO | 927.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| CPHR.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.2% | 0.7% | 3.4% |
| 1Y | 70.3% | 43.5% | 29.7% |
Return vs Industry: CPHR.F exceeded the US Pharmaceuticals industry which returned 37.6% over the past year.
Return vs Market: CPHR.F exceeded the US Market which returned 25.7% over the past year.
Price Volatility
| CPHR.F volatility | |
|---|---|
| CPHR.F Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: CPHR.F has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CPHR.F's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Craig Mull | www.cipherpharma.com |
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients. The company’s licensed products comprise Absorica, an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Conzip, an opioid agonist for the management of moderate to moderately severe chronic pain in adults; and Lipofen, an adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, as well as to increase HDL-C.
Cipher Pharmaceuticals Inc. Fundamentals Summary
| CPHR.F fundamental statistics | |
|---|---|
| Market cap | US$341.33m |
| Earnings (TTM) | US$27.33m |
| Revenue (TTM) | US$50.45m |
Is CPHR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPHR.F income statement (TTM) | |
|---|---|
| Revenue | US$50.45m |
| Cost of Revenue | US$10.03m |
| Gross Profit | US$40.42m |
| Other Expenses | US$13.09m |
| Earnings | US$27.33m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.08 |
| Gross Margin | 80.12% |
| Net Profit Margin | 54.17% |
| Debt/Equity Ratio | 4.0% |
How did CPHR.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 17:53 |
| End of Day Share Price | 2026/04/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cipher Pharmaceuticals Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Novak | ATB Cormark Historical (Cormark Securities) |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |